Vaccine Pharmacovigilance: Background Rates, Batch Signals and Administration Errors

Vaccines are given to large, healthy populations, often in campaigns, so coincidental events are reported in volume. EMA’s GVP guidance on vaccines asks marketing authorisation holders to place every report in context, using background rates, batch information and the circumstances of administration.

Why vaccines need their own approach

EMA’s GVP product- and population-specific considerations for vaccines recognise that vaccine safety signals can involve reduced efficacy, vaccine failure and batch-specific quality deviations as well as adverse reactions. A serious event reported after vaccination becomes a signal only if a causal link is plausible, and that judgement needs clinical detail, vaccination history, brand name, batch number and route of administration.

Background rates and observed-versus-expected analysis

Observed-versus-expected analysis is a routine tool, especially in mass vaccination. It places reports in context but cannot establish causality. The guidance asks for background incidence rates by age and sex to be kept up to date, and for sensitivity analyses that take account of under-reporting, diagnostic certainty, exposure and uncertainty in the background rate. Where rates are missing, a study may be needed to obtain them.

Disproportionality analyses should compare groups with similar background risk, stratified by factors such as age, region and season. Unrelated events, such as sudden infant death, attract reports simply because of the age at vaccination.

Batch and lot issues

  • Clusters across several regions strengthen a batch signal, while an apparent signal confined to one area may be a false one.
  • Recall or quarantine decisions must weigh the public health risk against the effect on supply.
  • A quality deviation may raise reactogenicity without posing a clinical risk.

Administration errors and immunisation stress

Typical errors include cold-chain breaks, wrong route, dose or diluent, schedule non-adherence, look-alike packaging and dilution problems with multi-dose vials. According to the guidance, error reports without an adverse reaction are not submitted as ICSRs but are considered in the PSUR. Anxiety-related reactions such as syncope should likewise be analysed in the PSUR, and communication should help prevent them.

Preparing before a campaign

For mass campaigns, the guidance stresses agreeing collaboration and information exchange between the parties beforehand. These include the MAH, national authorities, EMA, healthcare professionals and public health bodies. Decide who receives which report, how batch data reach the safety team and what rapid analyses will run in the first weeks.

How PQRA helps

PQRA can help vaccine marketing authorisation holders set up background rate libraries, observed-versus-expected procedures, batch signal workflows and PSUR content for administration errors, and prepare for local requirements in Greece and other EU markets.

Contact PQRA to discuss your vaccine safety processes.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *